Concepedia

WT1 Enhances Proliferation and Impedes Apoptosis in KRAS Mutant NSCLC via Targeting cMyc

Chen Wu, Sihan Wang, Caihua Xu, Andreas Tyler, Xingru Li, Charlotta Andersson, Yusuke Oji, Haruo Sugiyama, Yijiang Chen, Aihong Li

Cellular Physiology and Biochemistry · 2015 · 23 citations · 37 references

DOIFull text

Open access

Abstract

The results suggest that WT1 and c-MYC expression is important for survival in KRAS mutant tumors as opposed to KRAS wild-type tumors. For treatment of KRAS mutant NSCLC, targeting WT1 and cMyc may provide alternative therapeutic strategies.

References

37

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Tony Mok, Yi‐Long Wu, Sumitra Thongprasert et al. · New England Journal of Medicine · 2009 · 8.2K citations · Full text

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi et al. · New England Journal of Medicine · 2010 · 5.5K citations

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe et al. · The Lancet Oncology · 2009 · 4.1K citations

, , +10

AJCC Cancer Staging Manual. 6th ed

FL Greene, DL Page, Fleming Id et al. · 2002 · 2.3K citations

, , +7

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

William Pao, Theresa Y. Wang, Gregory J. Riely et al. · PLoS Medicine · 2005 · 1.5K citations · Full text